Scilex Holding (SCLX) Income from Non-Controlling Interests (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Income from Non-Controlling Interests of $900000.0 for Q1 2026, down 90.91% on a QoQ basis from $9.9 million in Q4 2025.
Scilex Holding (SCLX) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Income from Non-Controlling Interests for 3 consecutive years, with $900000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests changed N/A year-over-year to $900000.0; the TTM figure through Mar 2026 stood at $12.3 million (changed N/A YoY), while the FY2025 annual figure was $11.8 million, changed N/A from the prior year.
- Income from Non-Controlling Interests came in at $900000.0 for Q1 2026 at Scilex Holding, down from $9.9 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $9.9 million in Q4 2025, with the low at $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | 9.90 Mn |
| Sep 30, 2025 | 200,000.00 |
| Mar 31, 2021 | 1.33 Mn |